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Abstract
Background: Long chain polyunsaturated fatty acids (LCPUFAs) including docosahexaenoic acid and arachidonic acid are
suspected to play a key role in the pathogenesis of diabetes. LCPUFAs are known to be preferentially concentrated in
specific phospholipids termed as plasmalogens. This study was aimed to highlight potential changes in the metabolism of
phospholipids, and particularly plasmalogens, and LCPUFAs at various stages of diabetic retinopathy in humans.
Methodology and Principal Findings: We performed lipidomic analyses on red blood cell membranes from controls and
mainly type 2 diabetes mellitus patients with or without retinopathy. The fatty acid composition of erythrocytes was
determined by gas chromatography and the phospholipid structure was determined by liquid chromatography equipped
with an electrospray ionisation source and coupled with a tandem mass spectrometer (LC-ESI-MS/MS). A significant
decrease in levels of docosahexaenoic acid and arachidonic acid in erythrocytes of diabetic patients with or without
retinopathy was observed. The origin of this decrease was a loss of phosphatidyl-ethanolamine phospholipids esterified
with these LCPUFAs. In diabetic patients without retinopathy, this change was balanced by an increase in the levels of
several phosphatidyl-choline species. No influence of diabetes nor of diabetic retinopathy was observed on the
concentrations of plasmalogen-type phospholipids.
Conclusions and Significance: Diabetes and diabetic retinopathy were associated with a reduction of erythrocyte LCPUFAs
in phosphatidyl-ethanolamines. The increase of the amounts of phosphatidyl-choline species in erythrocytes of diabetic
patients without diabetic retinopathy might be a compensatory mechanism for the loss of LC-PUFA-rich phosphatidyl-
ethanolamines.
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Introduction
Diabetic retinopathy (DR) is a microvascular complication of
diabetes representing the first cause of blindness in the US and
Europe before the age of 50 [1]. The activation of biochemical
pathways by hyperglycemia, such as protein kinase C (PKC),
aldolase-reductase and/or advanced glycation endproducts path-
ways, and oxidative pathways leads to retinal ischemia by
extensive capillary abnormalities [2,3]. Among them, capillary
occlusions lead to retinal ischemia and pre-retinal neovascular-
ization through Vascular Endothelial Growth Factor (VEGF)
production [4]. Neovascular processes are further responsible for
vision threatening complications such as tractional retinal detach-
ment or neovascular glaucoma.
Long chain polyunsaturated fatty acids (LCPUFAs) including
docosahexaenoic acid (DHA, C22:6n-3) and arachidonic acid (AA,
C20:4n-6) are suspected to play key functions in the pathogenesis
of diabetes as glucose and lipid metabolisms are closely related [5].
Indeed, a shift from unsaturated to saturated fatty acids in cell
membranes, as observed at preclinical stages of diabetes, is
suspected to reduce erythrocytes deformability and subsequently
oxygen supply to tissues, thus promoting microvascular complica-
tions of diabetes [6]. Modifications in lipid composition is also
suspected to impact glucose effectiveness and insulin sensitivity, as
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shown by a recent meta-analysis on n-3 LCPUFA bioavailability
and insulin sensitivity [7]. LCPUFAs from the n-3 family have
been shown to inhibit many cellular and biochemical processes
involved in the pathophysiology of DR, namely the PKC, aldolase
reductase, and advanced glycation endproducts pathways, as well
as the expression of VEGF, the loss of pericytes, and platelet
aggregation [5].
As for the brain, the retina is characterized by its high content in
LCPUFAs carried by phospholipids [8–10]. These phospholipids
consist of a glycerol backbone connected to two fatty acid radicals
at the sn-1 and sn-2 positions, and to a polar head group at the sn-
3 position of glycerol. Depending on the nature of the polar head-
group, the two main classes of phospholipids are phosphatidyl-
ethanolamine (PE) and phosphatidyl-choline (PC). As for other
tissues or cell types, retinal phospholipids also consist of particular
phospholipids called plasmalogens, which have a fatty alcohol
radical and a vinyl-ether bond at sn-1 instead of a fatty acid radical
[11]. As with conventional phospholipids, plasmalogens are
classified according to their sn-3 position, the most abundant
plasmalogens being plasmenyl-ethanolamine (PlsE) and plasmenyl-
choline (PlsC). Because of the preferential esterification of
LCPUFAs at their sn-2 position [12–14], plasmalogens are
considered as reservoirs of LCPUFAs in membranes.
Several studies have shown modifications of the fatty acid but
also of the phospholipid content of cell membranes in human
diabetic patients and in animal models of diabetes [15–18].
However, the specific contribution of plasmalogens was not
investigated so far, especially in diabetic retina where LCPUFAs
were shown to prevent the retinal vascular damage caused by
diabetes [19]. The aim of our work was to highlight potential
changes in the metabolism of LCPUFAs in relationship with their
phospholipid origin in DR. For that purpose, we performed
lipidomic analyses of phospholipids in erythrocyte membranes
from diabetic patients with or without retinopathy.
Materials and Methods
Ethics Statement
Collection of the samples from subjects was conducted in
accordance with the guidelines of the Declaration of Helsinki. A
written consent was obtained and the protocol was accepted by the
local ethics committee (CPP Est I, Faculty of Medicine, Dijon,
France).
Selection of the human subjects and sample collection
Control subjects and type 1 or 2 diabetes mellitus patients were
recruited in the Department of Ophthalmology, University
Hospital, Dijon, France between June 2011 and April 2012.
Histories of panretinal photocoagulation, laser macular grid or
intravitreal injections of anti-VEGF or corticosteroids were
considered as exclusion criteria. No subject treated with statin or
any hypolipidemic drug was included in the study. The staging of
DR was determined after pupillary dilation on fundus photographs
(Visucam Pro NM retinal camera, Zeiss Meditec, Le Pecq, France)
of 8 peripheral retina fields by using the classification of the Early
Treatment Diabetic Retinopathy Study (ETDRS) [20]. Absence of
diabetes mellitus among control subjects was confirmed by glucose
fasting test (data not shown). A blood sample was collected at the
time of the ophthalmologic examination in heparinized tubes by
venipuncture. Triglycerides and total-, LDL- and HDL-cholesterol
were quantified by standard automatic analyzers at the Clinical
Chemistry Department of the University Hospital (Dijon, France).
Red blood cells were separated from plasma by centrifugation at
3000 rpm for 10 min at +4uC. All samples were immediately
stored at –80uC until further analyses.
Lipid analyses
Lipid extraction from erythrocytes. Lipids were extracted
from erythrocytes according to Moilanen and Nikkari [21].
Phospholipids were purified from total lipid extracts using silica
cartridges as previously described [9,22,23]. Phospholipid extracts
were stored under inert gas until further analyses.
Fatty acid analysis by gas chromatography. Total phos-
pholipids from red blood cells were transmethylated using boron
trifluoride in methanol according to Morrison and Smith [24].
Fatty acid methyl esters (FAMEs) and dimethylacetals (DMAs)
were subsequently extracted with hexane and analyzed on a
Hewlett Packard Model 5890 gas chromatograph (Palo Alto, CA,
USA) using a CPSIL-88 column (100 m60.25 mm i.d., film
thickness 0.20 mm; Varian, Les Ulis, France) equipped with a
flame ionization detector. Hydrogen was used as carrier gas (inlet
pressure 210 kPa). The oven temperature was held at 60uC for
5 min, increased to 165uC at 15uC/min and held for 1 min, and
then to 225uC at 2uC/min and finally held at 225uC for 17 min.
The injector and the detector were maintained at 250uC. FAMEs
and DMAs were identified by comparison with commercial and
synthetic standards. The data were processed using the EZChrom
Elite software (Agilent Technologies, Massy, France) and reported
as a percentage of the total fatty acids.
Structural analysis of phospholipids by LC-ESI-
MS. Prior to LC-ESI-MS analyses, the phosphorus content of
total phospholipid extracts was determined according to Bartlett
and Lewis [25]. After the internal standards dimyristoyl-sn-
glycerol-3-phosphatidylethanolamine (PE14:0/14:0) and dimyris-
toyl-sn-glycerol-3-phosphatidylcholine (PC14:0/14:0) in chloro-
form/methanol (1:1, v/v) were added, samples were stored at
280uC under argon atmosphere.
The structural analysis of phospholipids was performed according
to previously described procedures [9,26]. Briefly, liquid chroma-
tography separation was performed using a Hypersil Gold Silica
Column (150 mm62.1 mm i.d.63 mm, ThermoFinnigan, San
Jose, CA, USA) and a mobile phase consisting of: (A) hexane/
propan-2-ol/chloroform/water (44/43.5/10.5/2, v/v/v/v) con-
taining 12.5 mM of ammonium formate, and (B) hexane/propan-
2-ol/chloroform/water (34/49/10.5/6.5, v/v/v/v) containing
12.5 mM of ammonium formate. The solvent-gradient system
was as follows: 0 min A/B (%) 100/0, 10.5–24 min A/B (%) 22/78,
26.5–45 min A/B (%) 0/100% and 46–60 min A/B (%) 100/0.
The flow rate was of 300 mL.min21.
Mass spectrometry was performed using a ThermoFinnigan
TSQ Quantum triple quadrupole mass spectrometer (Thermo-
Finnigan, San Jose, CA, USA) equipped with a standard
electrospray ionisation source. Nitrogen was used as sheath and
auxiliary gas. The electrospray ionisation spray voltages were of 3
kV and 24.5 kV in negative and positive ion modes, respectively.
Vaporiser temperature was of 150uC, sheath gas N2 pressure 45
(arbitrary unit), auxiliary gas pressure 45 (arbitrary unit), ion sweep
gas pressure 5, ion transfer capillary temperature 300uC, skimmer
offset 5 V and multiplier gain 300,000.
PE and PC species were manually identified with the parent
mass information and their characteristic fragment ions in the CID
spectrum using a local database [9,26].
For all calculations, the ratio of peak area of each PC and PE
specie to the peak area of the internal standards (PC14:0/14:0 or
PE14:0/14:0, respectively) were used. Since the use of the neutral
loss of 141 Da is problematic in the quantification of PlsE [27],
quantification was based on multiple reaction monitoring (MRM)
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of one parent/fragment transition for each selected plasmalogen
whereas PE14:0/14:0 was considered as internal standard. The
standard curves were then plotted as ratio height of the respective
PlsE specie/height of PE14:0/14:0 versus the concentration. The
data were processed using the Xcalibur software (ThermoFinni-
gan). Corrections were applied to data for isotopic overlap.
Statistical analyses
Statistical analyses were performed using the Statistical Analysis
System (SAS Institute, Cary, NC, USA). Data with a normal
distribution are expressed as mean 6 standard deviation (SD) or
mean 6 standard error of the mean (SEM) whereas those having a
non-normal distribution are as median and interquartile range
[IQR]. The Kruskal-Wallis test was used to compare different groups
for continuous variables. The chi-square test was used to compare
dichotomous variables between the different groups. A post-test was
done using the post-hoc Dunn’s test. The tests were two-tailed and P
values lower than 0.05 were considered as statistically significant.
Results
Patient characteristics are displayed in Table 1. We included
102 individuals, 53 men and 49 females. These were 18 control
subjects, 14 diabetic patients without DR, 12 mild non-proliferative
DR patients, 12 moderate non-proliferative DR patients, 22 severe
non-proliferative DR patients, and 24 proliferative DR patients.
Our population was almost exclusively composed of type 2 diabetic
patients. The number of type 1 diabetic patient in each group was
very low and the ratio of type 1/type 2 diabetes was not statistically
different among groups (P= 0.27). There was no significant
difference for age (P= 0.58) and gender (P= 0.91) between groups.
HBA1c level did not differ between diabetic patients subgroups
(P= 0.44). All patients displayed normal values of plasma triglyc-
erides, total-, LDL- and HDL-cholesterol. No difference was
observed between the study groups on plasma lipid parameters.
There was no significant difference for the rate of diabetic
nephropathy between the groups of diabetic patients (P= 0.42) or
for macrovascular complications of diabetes such as coronaropathy,
peripheral arteriosclerosis (P= 0.84 and P=0.59, respectively).
Alteration of erythrocyte levels of omega-3 and omega-6
PUFAs in diabetic subjects with or without retinopathy
The complete fatty acid composition of erythrocytes from
control subjects and diabetic patients is presented in Table 2. The
most striking difference between controls and diabetic patients
with or without retinopathy was an alteration of the relative
amounts of docosahexaenoic acid (DHA, C22:6n-3, Figure 1),
and arachidonic acid (AA, C20:4n-6). These changes were
balanced by a relative increase in saturated fatty acids (C16:0,
C18:0, and C24:0) and monounsaturated fatty acids (C18:1n-9
and C24:1n-9,). The modification of erythrocyte concentrations of
DHA and AA had consequences on the amounts of total n-3
PUFAs which was significantly lowered in all patient groups (P,
0.05,), as well as on total n-6 PUFAs that were decreased in
patients with mild, moderate and severe DR (P,0.05) when
compared to controls. The variations observed in total PUFAs had
a minor impact on the n-6 PUFA to n-3 PUFA ratio.
No involvement of plasmenyl-cholines and plasmenyl-
ethanolamines in the alteration of erythrocyte levels of
PUFAs in patients with DR
As fatty acids can be esterified on several subtypes of
phospholipids in cell membranes, we have investigated the origin
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of the loss of erythrocyte DHA and AA by performing quantitative
analyses of individual phospholipid species having phospho-
choline (PC and PlsC) and phospho-ethanolamine (PE and PlsE)
headgroups. As shown in Table 3 and Table 4, the cause of the
lower levels of DHA and AA in erythrocytes was not related to a
specific loss of individual species of PlsC and PlsE esterified with
these PUFA, as their concentrations were not or only slightly
modified.
The loss of N-6 and N-3 PUFAs in patients with DR is the
consequence of modifications of erythrocyte levels of PE
Except for specific modifications in diabetic subjects without
retinopathy, no major change was observed in individual species of
PC esterified or not to DHA and AA in patients with DR
(Table 3). Only the concentrations of PC18:0:22:6 were signif-
icantly lowered in patients with severe and proliferative DR when
compared to controls (P,0.05).
Contrary to PC species, erythrocyte concentrations of individual
species of PE were largely modified in all diabetic patients having
or not a retinopathy (Table 4). These changes were concentrated
to PE species esterified either to both AA and DHA (PE20:4/22:6),
or to DHA or AA only (PE18:0/22:6, PE18:1/22:6, PE18:2/20:4+
PE16:0/22:6) (Figure 2). The alteration of the concentrations of
these PE species lowered the total pool of PE esterified to DHA in
all diabetic patients with or without retinopathy when compared
to controls (P,0.05). However, since these modifications were at
least partly balanced by an increase in the concentrations of other
PE species (particularly PE16:0/18:1), they had no consequence
on the amount of total PE except for patients with moderate and
proliferative DR.
Specific alterations in the concentrations of individual
species of PC and PlsC in diabetic subjects without
retinopathy
Diabetic subjects without retinopathy were characterized by
specific modifications in PC and PlsC species that were not
observed in controls or in diabetic patients with DR (Table 3).
These changes consisted in significantly increased levels of PC or
PlsC species esterified with saturated and/or monounsaturated
fatty acids (namely PC16:0/16:1, PC16:0/16:0, PC16:0/18:1,
PC18:1/18:1, PC18:0/18:1, PlsC18:1/18:0, PlsC18:0/18:0, and
PlsC18:1/22:1, P,0.05) or with PUFAs including AA and DHA
(namely PC18:1/18:2, PC16:0/20:3, PC18:0/18:2, PC18:0/20:2,
PC18:1/22:6, PC20:6/22:6, PC20:3/22:6, PC20:4/22:6,
PC20:5/22:4, PC22:6/22:6, PlsC16:0/22:6, and PlsC18:1/22:4,
P,0.05). As a consequence, the total amount of phospholipids
having a phospho-choline headgroup was significantly increased in
erythrocytes from these subjects (median [IQR] for total PlsC of
22.06 [19.22–23.94] and 27.41 [20.61–35.60] mg of mg of
phospholipids in control subjects and diabetic patients without
retinopathy, respectively, P,0.05; median [IQR] for total PC +
PlsC of 272.68 [240.85–299.96] and 335.43 [280.23–460.04] mg
of mg of phospholipids in control subjects and diabetic patients
without retinopathy, respectively, P,0.05).
Figure 1. Red blood cell membrane levels of docosahexaenoic acid (DHA), total n-3 PUFA, n-6 PUFA, and total n-6 PUFA/total n-3
PUFA in control subjects and diabetic patients with or without DR. Results are expressed as means 6 SEM. * based on Kruskall-Wallis test
(P,0.05).
doi:10.1371/journal.pone.0106912.g001
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Discussion
Our study pointed out several quantitative changes in erythro-
cyte lipids in diabetic patients with or without DR. To our
knowledge, this kind of lipidomic study following different stages of
retinal microvascular complication of diabetes has never been
performed before and represents the largest series of diabetic
patients in a lipidomic study. As our study included almost
exclusively type 2 diabetic patients, our observations are likely to
be restricted to this type of diabetes.
Our data has shown a global decrease in the levels of n-3 and n-6
LCPUFAs in erythrocyte membranes in all diabetic patients
independently from the stage of retinopathy. This decrease in LC-
PUFAs was balanced by increased levels of saturated and
monounsaturated fatty acids. The structural analysis of phospho-
lipids by LC-ESI-MS enabled us to determine which phospholipid
species were quantitatively affected by these changes. Whereas
plasmalogens were not implicated, our results showed reduced
concentrations of PE species esterified with DHA and AA in all
diabetic patients balanced by an increase in PE esterified with
saturated fatty acids. Total levels of PC and PlsC were unaffected in
DR, but increased in diabetic patients without retinopathy. The
alteration of LCPUFA levels in diabetic patients was not related to
PlsC or PlsE.
Our results are in accordance with previous observations on
diabetic patients and animal models of diabetes. In diabetic rats,
LC-ESI MS analyses on myocardial cells showed a 27%-decrease
in the levels of PE esterified with AA and DHA without any
modification of PC amounts. However, a 44%-increase in PlsE
and phosphatidyl-inositol contents was described [15]. In another
study on diabetic rat myocardial cells, a significant decrease in AA
and DHA in PC and PE and a higher phospholipase A2 activity
were observed [16]. These changes were associated to increased
concentrations of PlsE, suspected to be a protective mechanism
against insulin metabolism changes. In pregnant women affected
by gestational diabetes, a shift from unsaturated fatty acids to
saturated and monounsaturated fatty acids was observed in
erythrocytes [17]. In addition to confirming comparable alter-
ations in patients with DR, our data show a specific increase in the
concentrations of several PC and PlsC species esterified with
monounsaturated fatty acids in diabetic patients without retinop-
athy. We hypothesize that this may be the result of an ultimate
compensatory mechanism to balance the loss of AA- and DHA-
rich PE species observed in diabetes.
One cause of the reduction of the unsaturation index (switch
from unsaturated to more saturated fatty acids) of cell membranes
could be related to a decreased activity of delta-5 and delta-6
desaturase enzymes that are responsible for the biosynthesis of
LCPUFAs. Indeed, the activity of these enzymes was shown to be
modified in diabetes [28].
Such biochemical modifications in red blood cell membranes
are suspected to play a key role in the pathophysiology of diabetes
as they alter the permeability and the viscoelastic properties of
membranes [29,30]. A direct consequence would be a reduction of
erythrocytes deformability, thus promoting microvascular compli-
cations of diabetes as cellular deformability is a critical factor
modulating blood flow in microcapillaries [31]. This hypothesis
was corroborated by two works showing an association between
reduced deformability of erythrocytes and microvascular compli-
cations in diabetic patients [32,33]. It was also hypothesized that
increased membrane rigidity resulting from a decreased unsatu-
ration index inhibits the integration of insulin-dependent glucose
receptors (GLUT4) into plasma membrane, thus reducing glucose
effectiveness and resulting in increased insulin secretion. This was
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confirmed by Borkman et al., who described a correlation between
LCPUFA concentrations in membrane phospholipids of skeletal
muscle cells and insulin sensitivity [34].
Such modifications in LCPUFAs bioavailability make also
attractive the hypothesis of an impact of the reduced unsaturation
index on endothelial function. This idea is supported by data from
a study on human retinal vascular endothelial cells treated with
VEGF and pro-inflammatory cytokines, and showing that a pre-
treatment with DHA inhibits cellular inflammation through the
NF-kB pathway [35]. Other studies reported the protective effects
of n-3 LCPUFAs on other biochemical pathways involved in DR
pathophysiology, namely the PKC pathway promoting VEGF
release through diacylglycerols [36], the inducible nitric oxide
synthase pathway producing free radicals [37], the endothelin-1
pathway processing vasoconstriction [38], and protein glycosyla-
tion [39]. On the other hand, another n-3 LCPUFA, eicosapen-
tanoic acid, is known to prevent pericyte degeneration [40].
Finally, Tikhonenko and collaborators have recently reported a
preservation of retinal capillaries in diabetic rats supplemented
with DHA [19]. This was associated with an enhanced life span
and a reduction of retinal inflammatory markers, suggesting
potential benefits of n-3 LCPUFA supplementation in the
prevention of DR in diabetic patients.
Our study has several limitations which are, i) the absence of
serine- and inositol-esterified phospholipids in our analyses, ii) the
absence of statistical difference for glycated hemoglobin between
Figure 2. Red blood cell membrane levels of selected phospatidyl- ethanolamine (PE) species esterified with docosahexaenoic acid
(22:6 or DHA,) and/or arachidonic acid (20:4 or AA), and total PE esterified or not with DHA in control subjects and diabetic
patients with or without DR. Results are expressed as means 6 SEM. * based on Kruskall-Wallis test (P,0.05).
doi:10.1371/journal.pone.0106912.g002
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patients with or without DR, iii) the absence of evaluation of
dietary intake of LCPUFAs. Moreover, the rate of macro-vascular
and micro-vascular complications of diabetes of our cohort
increased with the progression of diabetic retinopathy without
any statistical significance between the groups, probably due to the
size of the cohort. Still, these rates are in the range of those
reported in the literature and we do not exclude that the
modifications observed in red blood cell lipids may also relate
these complications, and iv) due to the recruitment of our patients
in our series, we cannot draw firm conclusion for type 1 diabetic
patients because they were poorly represented. Finally, an
increased number of subjects would have sharpened our results,
and a long term follow-up would have enabled us to determine the
effect of a better control of diabetes on the lipid composition of
erythrocyte membranes.
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